ArticleJournal of cancer research and clinical oncology2015
Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer.
Article in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Potential Prognostic and Metastatic Implications of MACC1 and MMP8 in Colorectal Cancer.Current issues in molecular biology · 2026Article
- MACC1 revisited - an in-depth review of a master of metastasis.Biomarker research · 2024Review
- Global Proteomics Analysis of Lysophosphatidic Acid Signaling in PC-3 Human Prostate Cancer Cells: Role of CCN1.International journal of molecular sciences · 2024Article
- MACC1-induced migration in tumors: Current state and perspective.Frontiers in oncology · 2023Review
- MACC1 Is Associated With Epithelial-Mesenchymal Transition and Can Predict Poor Prognosis in Nasopharyngeal Carcinoma.Frontiers in oncology · 2021Article
- Messenger RNA enrichment using synthetic oligo(T) click nucleic acids.Chemical communications (Cambridge, England) · 2020Article
- Article
- Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response.Cancers · 2019Article
- Prognostic and Risk Stratification Value of Lesion MACC1 Expression in Colorectal Cancer Patients.Frontiers in oncology · 2019Article
- A panel consisting of three novel circulating lncRNAs, is it a predictive tool for gastric cancer?Journal of cellular and molecular medicine · 2018Article
- Article
- Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.Oncology letters · 2017Article
- YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.Oncotarget · 2017Article
- Underlying Mechanisms for Distant Metastasis - Molecular Biology.Visceral medicine · 2017Review
- Article
- Metastasis-associated in colon cancer-1 and aldehyde dehydrogenase 1 are metastatic and prognostic biomarker for non-small cell lung cancer.BMC cancer · 2016Article
- Increased MACC1 levels in tissues and blood identify colon adenoma patients at high risk.Journal of translational medicine · 2016Article
- Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.American journal of human genetics · 2016Article
- ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.International journal of clinical and experimental pathology · 2015Article
- Long Noncoding RNA FGD5-AS1 Knockdown Decrease Viability, Migration, and Invasion of Non-Small Cell Lung Cancer (NSCLC) Cells by Regulating the MicroRNA-944/MACC1 Axis.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetastasis-associated in colon cancer-1 (MACC1) is a newly identified gene that plays an important role in cancer progression and metastasis. MACC1 has important functions in the differentiation, invasion, and metastasis of nonsmall cell lung cancer (NSCLC). However, the value of circulating MACC1 as a potential diagnostic and prognostic biomarker for NSCLC remains unknown.
methodsPlasma MACC1 mRNA levels were examined in 272 patients with NSCLC, 61 with benign lung disease, and 80 healthy volunteers using reverse transcription quantitative real-time polymerase chain reaction.
resultsMACC1 was more highly expressed in NSCLC patients than in patients with benign disease (P < 0.001) or in healthy volunteers (P < 0.001). High MACC1 expression was significantly associated with NSCLC stage (P = 0.013) and lymph node metastasis (P = 0.016). The area under the receiver operating characteristic curve was 0.766, and the optimal cutoff value was 0.105, providing a sensitivity of 71.4 % and a specificity of 89.1 %. The diagnostic capability of circulating MACC1 mRNA was higher than that of carcinoembryonic antigen (P = 0.025) or cytokeratin-19 (P = 0.010). Furthermore, high MACC1 expression was associated with poor overall survival (OS) and disease-free survival (DFS) and predicted poor survival in NSCLC patients. Consequently, MACC1 mRNA was an independent prognostic factor of OS and DFS.
conclusionWe concluded that circulating MACC1 mRNA represents a potential noninvasive, diagnostic and prognostic marker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.